Provided by Tiger Trade Technology Pte. Ltd.

MannKind

3.90
+0.560016.77%
Post-market: 3.980.0800+2.05%19:58 EDT
Volume:15.02M
Turnover:56.94M
Market Cap:1.25B
PE:-27.86
High:4.03
Open:3.37
Low:3.30
Close:3.34
52wk High:6.51
52wk Low:2.23
Shares:321.54M
Float Shares:309.97M
Volume Ratio:3.92
T/O Rate:4.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1400
EPS(LYR):0.0200
ROE:32.74%
ROA:0.79%
PB:-18.66
PE(LYR):195.00

Loading ...

MannKind price target raised to $14 from $11 at Wells Fargo

TIPRANKS
·
Jul 30

Earning Preview: MannKind Q2 revenue expected to rise about 39%, institutional views tilt positive

Earnings Agent
·
Jul 30

MannKind Says Phase 1b Study Shows Idiopathic Pulmonary Fibrosis Treatment Generally Safe, Well-Tolerated

MT Newswires Live
·
Jul 29

MannKind Corp - Nintedanib DPI Generally Safe and Well Tolerated in Phase 1B Ipf Study

THOMSON REUTERS
·
Jul 29

MannKind Reports Positive Phase 1B Inflo-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in Ipf

THOMSON REUTERS
·
Jul 29

MannKind Corp - no Serious Adverse Events or Discontinuations Reported in Phase 1B Inflo-1 Study

THOMSON REUTERS
·
Jul 29

MannKind Reports Positive Phase 1b Inflo-1 Results for Inhaled Nintedanib in IPF

Reuters
·
Jul 29

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

GlobeNewswire
·
Jul 29

Health Rounds: MannKind Injection Helps Heart Failure Patients Avoid ER Infusions

Reuters
·
Jul 29

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Bruker (BRKR) and BrightSpring Health Services, Inc. (BTSG)

TIPRANKS
·
Jul 27

The Bull Case For MannKind (MNKD) Could Change Following FDA Approval Of At-Home Furoscix ReadyFlow Autoinjector – Learn Why

Simply Wall St.
·
Jul 25

MannKind Raises $50 Million in Private Placement

TIPRANKS
·
Jul 25

Mannkind Wins FDA Approval for Furoscix Readyflow Autoinjector to Treat Edema in Adults with Heart Failure or CKD

Reuters
·
Jul 25

U.S. Stocks on the Move-booz Allen Hamilton, Sensient, Amkor

Reuters
·
Jul 24

MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says

MT Newswires Live
·
Jul 24

Mannkind Corp Shares up 3.4% as FDA Approves Drug-device Combo for Fluid Buildup

THOMSON REUTERS
·
Jul 24

U.S. Stocks on the Move-tenet Healthcare, Intel, Verizon

Reuters
·
Jul 24

MannKind Agrees to $50 Million Private Stock Sale

MT Newswires Live
·
Jul 24

Mannkind Climbs as FDA Approves Drug-device Combo for Fluid Buildup

Reuters
·
Jul 24

MannKind's Furoscix ReadyFlow Injection Approved by US FDA

MT Newswires Live
·
Jul 24